tetano
Editor, Senior Moderator
iScience
. 2022 Dec 1;105690.
doi: 10.1016/j.isci.2022.105690. Online ahead of print.
mRNA vaccines elicit potent neutralization against multiple SARS-CoV-2 Omicron subvariants and other variants of concern
Gang Wang[SUP] 1 [/SUP], Juan Shi[SUP] 1 [/SUP], Abhishek K Verma[SUP] 2 [/SUP], Xiaoqing Guan[SUP] 1 [/SUP], Stanley Perlman[SUP] 2 3 [/SUP], Lanying Du[SUP] 1 [/SUP]
Affiliations
Abstract
SARS-CoV-2 variants of concern (VOCs) have shown resistance to vaccines targeting the original virus strain. An mRNA vaccine encoding the spike protein of Omicron BA1 (BA1-S-mRNA) was designed, and its neutralizing activity, with or without the original receptor-binding domain (RBD)-mRNA, was tested against SARS-CoV-2 VOCs. First-dose of BA1-S-mRNA followed by two-boosts of RBD-mRNA elicited potent neutralizing antibodies (nAbs) against pseudotyped and authentic original SARS-CoV-2; pseudotyped Omicron BA1, BA2, BA2.12.1 and BA5 subvariants, and Alpha, Beta, Gamma and Delta VOCs; authentic Omicron BA1 subvariant and Delta VOC. By contrast, other vaccination strategies, including RBD-mRNA first-dose plus BA1-S-mRNA two-boosts, RBD-mRNA or BA1-S-mRNA three-doses, or their combinations, failed to elicit high nAb titers against all of these viruses. Overall, this vaccination strategy was effective for inducing broadly and potent nAbs against multiple SARS-CoV-2 VOCs, particularly Omicron BA5, and may guide the rational design of next-generation mRNA vaccines with greater efficacy against future variants.
Keywords: COVID-19; Coronavirus; Neutralizing antibodies; Omicron subvariants; SARS-CoV-2; Variants of concern.
. 2022 Dec 1;105690.
doi: 10.1016/j.isci.2022.105690. Online ahead of print.
mRNA vaccines elicit potent neutralization against multiple SARS-CoV-2 Omicron subvariants and other variants of concern
Gang Wang[SUP] 1 [/SUP], Juan Shi[SUP] 1 [/SUP], Abhishek K Verma[SUP] 2 [/SUP], Xiaoqing Guan[SUP] 1 [/SUP], Stanley Perlman[SUP] 2 3 [/SUP], Lanying Du[SUP] 1 [/SUP]
Affiliations
- PMID: 36471872
- PMCID: PMC9711903
- DOI: 10.1016/j.isci.2022.105690
Abstract
SARS-CoV-2 variants of concern (VOCs) have shown resistance to vaccines targeting the original virus strain. An mRNA vaccine encoding the spike protein of Omicron BA1 (BA1-S-mRNA) was designed, and its neutralizing activity, with or without the original receptor-binding domain (RBD)-mRNA, was tested against SARS-CoV-2 VOCs. First-dose of BA1-S-mRNA followed by two-boosts of RBD-mRNA elicited potent neutralizing antibodies (nAbs) against pseudotyped and authentic original SARS-CoV-2; pseudotyped Omicron BA1, BA2, BA2.12.1 and BA5 subvariants, and Alpha, Beta, Gamma and Delta VOCs; authentic Omicron BA1 subvariant and Delta VOC. By contrast, other vaccination strategies, including RBD-mRNA first-dose plus BA1-S-mRNA two-boosts, RBD-mRNA or BA1-S-mRNA three-doses, or their combinations, failed to elicit high nAb titers against all of these viruses. Overall, this vaccination strategy was effective for inducing broadly and potent nAbs against multiple SARS-CoV-2 VOCs, particularly Omicron BA5, and may guide the rational design of next-generation mRNA vaccines with greater efficacy against future variants.
Keywords: COVID-19; Coronavirus; Neutralizing antibodies; Omicron subvariants; SARS-CoV-2; Variants of concern.